Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ZFP36L2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ZFP36L2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ZFP36L2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ZFP36L2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ZFP36L2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZFP36L2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ZFP36L2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZFP36L2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZFP36L2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ZFP36L2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZFP36L2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ZFP36L2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007135622 | Breast | DCIS | cellular response to tumor necrosis factor | 33/1390 | 229/18723 | 1.84e-04 | 3.00e-03 | 33 |
GO:000640123 | Breast | DCIS | RNA catabolic process | 38/1390 | 278/18723 | 1.91e-04 | 3.08e-03 | 38 |
GO:000640223 | Breast | DCIS | mRNA catabolic process | 33/1390 | 232/18723 | 2.35e-04 | 3.70e-03 | 33 |
GO:190210521 | Breast | DCIS | regulation of leukocyte differentiation | 37/1390 | 279/18723 | 4.19e-04 | 5.65e-03 | 37 |
GO:190015321 | Breast | DCIS | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 6/1390 | 15/18723 | 4.62e-04 | 6.12e-03 | 6 |
GO:19031312 | Breast | DCIS | mononuclear cell differentiation | 51/1390 | 426/18723 | 4.88e-04 | 6.40e-03 | 51 |
GO:007037111 | Breast | DCIS | ERK1 and ERK2 cascade | 41/1390 | 330/18723 | 8.11e-04 | 9.32e-03 | 41 |
GO:003461222 | Breast | DCIS | response to tumor necrosis factor | 33/1390 | 253/18723 | 1.11e-03 | 1.21e-02 | 33 |
GO:000734612 | Breast | DCIS | regulation of mitotic cell cycle | 52/1390 | 457/18723 | 1.38e-03 | 1.43e-02 | 52 |
GO:190015122 | Breast | DCIS | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 6/1390 | 18/18723 | 1.41e-03 | 1.45e-02 | 6 |
GO:007136422 | Breast | DCIS | cellular response to epidermal growth factor stimulus | 10/1390 | 45/18723 | 1.43e-03 | 1.46e-02 | 10 |
GO:000095622 | Breast | DCIS | nuclear-transcribed mRNA catabolic process | 18/1390 | 112/18723 | 1.48e-03 | 1.50e-02 | 18 |
GO:007138422 | Breast | DCIS | cellular response to corticosteroid stimulus | 12/1390 | 61/18723 | 1.54e-03 | 1.54e-02 | 12 |
GO:003465522 | Breast | DCIS | nucleobase-containing compound catabolic process | 47/1390 | 407/18723 | 1.69e-03 | 1.68e-02 | 47 |
GO:004544421 | Breast | DCIS | fat cell differentiation | 30/1390 | 229/18723 | 1.70e-03 | 1.68e-02 | 30 |
GO:190136122 | Breast | DCIS | organic cyclic compound catabolic process | 55/1390 | 495/18723 | 1.75e-03 | 1.71e-02 | 55 |
GO:004670022 | Breast | DCIS | heterocycle catabolic process | 50/1390 | 445/18723 | 2.19e-03 | 2.03e-02 | 50 |
GO:007138522 | Breast | DCIS | cellular response to glucocorticoid stimulus | 11/1390 | 56/18723 | 2.42e-03 | 2.18e-02 | 11 |
GO:007084922 | Breast | DCIS | response to epidermal growth factor | 10/1390 | 49/18723 | 2.80e-03 | 2.43e-02 | 10 |
GO:001943922 | Breast | DCIS | aromatic compound catabolic process | 51/1390 | 467/18723 | 3.58e-03 | 2.92e-02 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZFP36L2 | SNV | Missense_Mutation | | c.376G>C | p.Glu126Gln | p.E126Q | P47974 | protein_coding | deleterious(0) | possibly_damaging(0.86) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ZFP36L2 | SNV | Missense_Mutation | | c.5N>G | p.Ser2Trp | p.S2W | P47974 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ZFP36L2 | SNV | Missense_Mutation | | c.469N>A | p.Glu157Lys | p.E157K | P47974 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EW-A1PA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ZFP36L2 | SNV | Missense_Mutation | novel | c.73N>T | p.Leu25Phe | p.L25F | P47974 | protein_coding | tolerated(0.61) | possibly_damaging(0.875) | TCGA-JL-A3YX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZFP36L2 | insertion | Frame_Shift_Ins | novel | c.111_112insG | p.Thr38AspfsTer46 | p.T38Dfs*46 | P47974 | protein_coding | | | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ZFP36L2 | SNV | Missense_Mutation | | c.57G>C | p.Glu19Asp | p.E19D | P47974 | protein_coding | tolerated(0.21) | benign(0.027) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
ZFP36L2 | SNV | Missense_Mutation | | c.137N>T | p.Ser46Leu | p.S46L | P47974 | protein_coding | deleterious(0) | benign(0.203) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
ZFP36L2 | SNV | Missense_Mutation | novel | c.635N>A | p.Cys212Tyr | p.C212Y | P47974 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZFP36L2 | SNV | Missense_Mutation | rs761179005 | c.401N>A | p.Leu134His | p.L134H | P47974 | protein_coding | tolerated(0.1) | probably_damaging(0.937) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZFP36L2 | SNV | Missense_Mutation | novel | c.423G>C | p.Gln141His | p.Q141H | P47974 | protein_coding | tolerated(0.11) | possibly_damaging(0.694) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |